| ￥800 | |
| Z05416-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity | > 95% as determined by BisTris PAGE | |
| Endotoxin Level | Less than 1EU per μg by the LAL method. | |
| Biological Activity | Human FcRn, His Tag captured on CM5 Chip via AntiHis Antibody can bind IgG4 Fc, Human in SPR assay (Biacore T200). Test result was comparable to standard batch. | |
| Expression System | HEK293 | |
| Theoretical Molecular Weight | 25.8 kDa | |
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 30-35 kDa based on Bis-Tris PAGE result. | |
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | |
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of IgG4 Fc, Human is greater than 95% as determined by SEC-HPLC. »
IgG4 Fc, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
Human FcRn, His Tag captured on CM5 Chip via Anti-His Antibody can bind IgG4 Fc, Human, No Tag with an affinity constant of 1.365 μM as determined in SPR assay (Biacore T200). »
| Target Background | It is known as a IgG4-related disease and its differentiation is based on the analysis of IgG4 levels in the affected tissues. The IgG4-related disease is considered to be a generalized pathological process involving a wide spectrum of various disorders that may affect distant organs. |
| Synonyms | IGHG4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
